Royal Marsden Hospital
UK Consortium Launches With Public-Private Funding to ID Immunotherapy Biomarkers
The Francis Crick Institute and the Royal Marsden Foundation Trust are spearheading the MANIFEST project with £21.9 million in government and industry funding.
Guardant Health, Royal Marsden Partner on Prospective Liquid Biopsy Trial in Early Colorectal Cancer
The study is evaluating the Guardant Reveal assay to guide chemotherapy treatment decisions following surgery for stage II to III colorectal cancer.
Kidney Cancer Study Links Checkpoint Immunotherapy Responses to T Cell Features
Researchers from the UK used integrated genomics to analyze prospectively collected samples from metastatic clear cell renal cell carcinoma patients.
RB1 Alterations in Advanced Prostate Cancer Associated With Poor Outcome
Using exome or transcriptome data from more than 400 metastatic, castration-resistant prostate cancer cases, researchers identified survival-related alterations in the RB1 gene.
Clinical Trial Results Support Liquid Biopsy Monitoring to Predict Responders to Palbociclib
Premium
A study reported this week that measuring changes in the numbers of specific circulating tumor DNA mutations can rapidly identify breast cancer patients who will have better outcomes.